Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France
This study will estimate the real-world effectiveness of adjuvant nivolumab therapy in adult participants with muscle invasive urothelial carcinoma (MIUC) in France.
Urothelial Carcinoma
DRUG: nivolumab
Disease-free survival (DFS) of participants, At months 3, 6, 9, 12, 18, 24, 30, 26, 48 and 60
Time to recurrence (TRR), At months 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60|Distance metastases-free survival (DMFS), At months 3, 6, 9, 12, 18, 24, 30, 26, 48 and 60|Non-urothelial tract recurrence free survival (NUTRFS), At months 3, 6, 9, 12, 18, 24, 30, 26, 48 and 60|Locoregional disease free survival (LRFDS), At months 3, 6, 9, 12, 18, 24, 30, 26, 48 and 60|Overall survival (OS), At months 3, 6, 9, 12, 18, 24, 30, 26, 48 and 60|Disease specific survival (DSS), At months 3, 6, 9, 12, 18, 24, 30, 26, 48 and 60|Second progression-free survival (PFS2), At months 3, 6, 9, 12, 18, 24, 30, 26, 48 and 60|Participant demographics, Baseline|Participant baseline clinical characteristics, Baseline|Participant history of other cancer(s, Baseline|Participant comorbidities pre-existing at the time of adjuvant therapy initiation, Index date|Participant renal function at treatment initiation, Day 1|Participant concomitant systemic treatment(s), Day 1 and at months 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60|Diagnosis of muscle-invasive urothelial carcinoma diagnosis, Baseline|Systemic neoadjuvant treatment history, Baseline|Surgery for muscle-invasive urothelial carcinoma, Baseline|Participant history of previous urothelial carcinoma, Baseline|PD-L1 status testing results, Baseline|Participant muscle Invasive urothelial carcinoma disease characteristics, At months 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60|Time from initial diagnosis of muscle invasive disease to adjuvant treatment initiation, At months 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60|Delay in adjuvant nivolumab treatment initiation related to post-operative complications, Baseline|Time from radical surgery to adjuvant nivolumab treatment initiation, At months 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60|Adjuvant nivolumab treatment duration, At months 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60|Number of adjuvant nivolumab treatment cycles, At months 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60|Dose adjuvant nivolumab per cycle, At months 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60|Reason for adjuvant nivolumab treatment interruption, At months 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60|Reason for adjuvant nivolumab treatment discontinuation, At months 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60|Non-systemic treatments prescribed post adjuvant nivolumab discontinuation, At months 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60|Systemic treatment prescribed post adjuvant nivolumab discontinuation, At months 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60|Participant response to prescribed systemic treatment post adjuvant nivolumab discontinuation, At months 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60|Participant adverse events, At months 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60|Participant reported outcomes as assessed by European Quality of Life-5 Dimensions (EQ-5D) Questionnaire, Prospective participants only, Baseline, and at months 3, 6, 9, 12, 18, 24, 30, and 36
This study will estimate the real-world effectiveness of adjuvant nivolumab therapy in adult participants with muscle invasive urothelial carcinoma (MIUC) in France.